Real-world effectiveness of treatments for type 2 diabetes, hypercholesterolemia, and hypertension in Canadian routine care – Results from the CardioVascular and metabolic treatment in Canada: Assessment of REal-life therapeutic value (CV-CARE) registry, 12-months results

• Published in: Diabetes research and clinical practice Vol. 170; p. 108416
• Main Authors: Goldenberg, Ronald, Bell, Alan, Cheng, Willoon, Fils-Aimé, Nadège, Burrows, Melonie, Blavignac, Jessica, Parron, Emilia, Barakat, Maxime
• Format: Journal Article
• Language: English
• Published: Ireland Elsevier B.V 01.12.2020
• Subjects: Aged; Anticholesteremic Agents - therapeutic use; Antihypertensive Agents - therapeutic use; Benzimidazoles - therapeutic use; Canada; Cardiovascular Diseases - drug therapy; Cardiovascular disorders; Chlorthalidone - therapeutic use; Colesevelam Hydrochloride - therapeutic use; Diabetes Mellitus, Type 2 - drug therapy; Female; Humans; Hypercholesterolemia; Hypercholesterolemia - drug therapy; Hypertension; Hypertension - drug therapy; Hypoglycemic Agents - therapeutic use; Male; Metabolic disorders; Metabolic Syndrome - drug therapy; Metformin - therapeutic use; Middle Aged; Oxadiazoles - therapeutic use; Prospective Studies; Registries; Registry-based study; Treatment Outcome; Type 2 diabetes; Canada; Type 2 diabetes; def; MetER; MetIR; PCSK9; AZI/CHL; HDL-C; DBP; RWE; mo; AE; T2D; DCCT; AZI; CVD; ARB; Hypercholesterolemia; Cardiovascular disorders; AV; CRF; SAE; FPG; Metabolic disorders; TXC; N/A; RCT; C; HTN; LDL-C; RAASi; HCh; BP; CHEP; ESC; UKPDS; ApoB; CKD; HbA1c; BMI; Hypertension; eGFR; SBP; GI; CCB; MedDRA; CI; SOC; TC; ACR; ACS; CCS; CV; TG; ACEi; Registry-based study
• ISSN: 0168-8227; 1872-8227
• DOI: 10.1016/j.diabres.2020.108416

•Achieving targets of cardiometabolic disease parameters crucial to delay complications.•RWE of the safety and efficacy of CV and metabolic drugs in Canada is scarce.•CV-CARE provides RWE in Canadian routine clinical care setting. The CV-CARE registry provides RWE in Canadian routine clinical practice. CV-CARE is a multi-site, observational, prospective Canadian registry enrolling patients initiating treatment with metformin hydrochloride extended-release (MetER) for T2D; colesevelam (C) for HCh; and azilsartan (AZI), azilsartan/chlorthalidone (AZI/CHL) or diltiazem extended-release (TXC) for HTN. Patient characteristics/assessment were performed at baseline and 12 ± 6 months. Primary outcome was absolute change in HbA1c and FPG (MetER); % change in LDL-C (C); and absolute change in BP (AZI-AZI/CHL-TXC). Of the 4194 patients in the primary analysis population, 24% were taking MetER, 39% were taking C, 33% were taking AZI, 12% were taking AZI/CHL, and 3% were taking TXC. At 12 months, MetER-treated patients had an absolute mean (95% CI) change in HbA1c of −0.3% [−0.4; −0.2] and in FPG of 0.7 mmol/L [−1.0; −0.4]. C-treated patients had a mean (95% CI) % change in LDL-C of −13.0% [−14.6; −11.4]. Absolute mean (95% CI) changes in SBP were −18.7 mmHg [−19.7; −17.7](AZI), −21.3 mmHg [−23.1; −19.5](AZI/CHL), and -12.3 mmHg [−15.1; −9.6](TXC). In a real-world Canadian setting, MetER, C, AZI, AZI/CHL, and TXC show improvement of the cardiometabolic profile of T2D, HCh, and HTN patients.